Automated oxygen therapy for patients with hypoxemic pneumonia
Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia
This study is testing if a new automated oxygen therapy can help people with hypoxemic pneumonia recover faster and spend less time in the hospital compared to standard oxygen treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT03527992 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of automated oxygen therapy in patients hospitalized with hypoxemic pneumonia. The study compares two groups: one receiving automated oxygen therapy that adjusts flow based on continuous monitoring of oxygen saturation, and another receiving standard oxygen therapy. The primary focus is to determine if automated therapy can reduce the length of hospital stays, duration of oxygen therapy, and associated medical costs. The trial aims to improve patient outcomes by minimizing complications related to prolonged hospitalization.
Who should consider this trial
Good fit: Ideal candidates are adults hospitalized for less than 48 hours with hypoxemic pneumonia and oxygen saturation below 94%.
Not a fit: Patients with hospital-acquired pneumonia or those requiring high-flow oxygen therapy or ventilatory support may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly shorten hospital stays and improve recovery for patients with hypoxemic pneumonia.
How similar studies have performed: Previous studies have shown that automated oxygen therapy is effective in COPD patients, suggesting potential success in this novel application for pneumonia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult * Patient living at home or in an institution * Patient hospitalized for less than 48 hours * Pneumonia defined (according to the 2006 French-speaking infectious pneumology society (SPILF) criteria) by: * respiratory functional symptoms (cough, sputum, dyspnea, chest pain) and * Hyperthermia \>38,5°C or hypothermia \<36°C and * Radiological Signs of Pneumonia * Hypoxia : SpO2 \< 94% in ambient air and/or PaO2\< 60 mmHg in ambient air Exclusion Criteria: * Pneumonia acquired at the hospital. * Patient hospitalized in another department more than 48 hours before admission * Chronic respiratory failure * Active neoplasia * Patients undergoing oxygen therapy and / or long-term NIV * Associated cardiac decompensation (clinical signs and / or NTproBNP\> 1800ng / mL) (3 * Initial Need for high flow oxygen therapy or ventilatory support (NIV, VI) * Difficulties expected from home support.
Where this trial is running
Toulouse
- CHU Larrey — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Elise Noel-Savina, MD — University Hospital, Toulouse
- Study coordinator: Elise Noel-Savina, MD
- Email: noel-savina.e@chu-toulouse.fr
- Phone: 5 67 77 16 90
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.